← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Lumithera, Inc.
Poulsbo, WA
$6,262,181
Total funding
4
Grants
Funding over time
peak $1.9M · FY2015–23$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,262,181 · 4
By mechanism
R44$5,509,263 · 2
R43$752,918 · 2
Investigators at Lumithera, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,502,600
R44 · FY2019 · EY
LIGHTSITE IIIB: Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,169,339
R44 · FY2023 · EY
Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients$1,025,600
R44 · FY2020 · EY
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$897,302
R44 · FY2020 · EY
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$674,742
R44 · FY2021 · EY
The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration$267,223
R43 · FY2015 · EY
A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration$256,010
R43 · FY2015 · EY
The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema$239,680
R44 · FY2022 · EY
A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration$140,000
R43 · FY2017 · EY
The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration$89,685
R43 · FY2017 · EY